<DOC>
	<DOCNO>NCT03036813</DOCNO>
	<brief_summary>A Phase 3 , Double-blind , Randomized , Placebo-controlled , Multicenter Study GBT440 Administered Orally Patients With Sickle Cell Disease</brief_summary>
	<brief_title>Study Evaluate Effect GBT440 Administered Orally Patients With Sickle Cell Disease ( GBT_HOPE )</brief_title>
	<detailed_description>This randomize , placebo-controlled , double blind , parallel group , multicenter study participant , age 12 65 year , SCD . The key purpose study establish efficacy safety GBT440 compare placebo .</detailed_description>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<criteria>1 . Male female study participant sickle cell disease 2 . Participants least 1 episode vasoocclusive crisis ( VOC ) past 12 month . 3 . Age 12 65 year 4 . Hemoglobin ( Hb ) ≥6.0 ≤10.5 g/dL screen 5 . For participant take hydroxyurea ( HU ) , dose HU ( mg/kg ) must stable least 3 month prior sign ICF . 1 . More 10 VOCs within past 12 month require hospital , emergency room clinic visit 2 . Patients receive regularly schedule blood ( RBC ) transfusion therapy ( also term chronic , prophylactic , preventive transfusion ) receive RBC transfusion reason within 28 day sign ICF 3 . Hospitalized sickle cell crisis vasoocclusive event within 14 day sign ICF ( i.e. , vasoocclusive event within 14 day prior sign ICF ) 4 . Hepatic dysfunction characterize alanine aminotransferase ( ALT ) &gt; 4 × upper limit normal 5 . Severe renal dysfunction ( estimate glomerular filtration rate Screening visit ; calculated central laboratory ) &lt; 30 mL/min/1.73 m^2 chronic dialysis</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>